Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance
Executive Summary
Sandoz' lawsuit against FDA over the human growth hormone product Omnitrope could further complicate the agency's efforts to define a potential approval route for "follow-on" biologics
You may also be interested in...
Novartis’ Biogeneric Pipeline Has Six Projects; Pricing Issues Are A Focus
Novartis expects to file its second biosimilar application in the coming year, Sandoz CEO Andreas Rummelt stated during the Swiss drug maker's first quarter sales and earnings call April 24
Novartis’ Biogeneric Pipeline Has Six Projects; Pricing Issues Are A Focus
Novartis expects to file its second biosimilar application in the coming year, Sandoz CEO Andreas Rummelt stated during the Swiss drug maker's first quarter sales and earnings call April 24
User Fee Program Renewal Gets Trickier After Ruling In Omnitrope Court Case
Renewal of FDA's Prescription Drug User Fee Act could be complicated by a federal court ruling that the agency must take action on Sandoz' application for a follow-on version of Pfizer's recombinant human growth hormone Genotropin